PT - JOURNAL ARTICLE AU - Otavio Cabral-Marques AU - Gilad Halpert AU - Lena F. Schimke AU - Yuri Ostrinski AU - Israel Zyskind AU - Miriam T. Lattin AU - Florian Tran AU - Stefan Schreiber AU - Alexandre H.C. Marques AU - Igor Salerno Filgueiras AU - Desirée Rodrigues Plaça AU - Gabriela Crispim Baiocchi AU - Paula Paccielli Freire AU - Dennyson Leandro M. Fonseca AU - Jens Y. Humrich AU - Tanja Lange AU - Antje Müller AU - Lasse M. Giil AU - Hanna Graßhoff AU - Anja Schumann AU - Alexander Maximilian Hackel AU - Juliane Junker AU - Carlotta Meyer AU - Hans D. Ochs AU - Yael Bublil Lavi AU - Kai Schulze-Forster AU - Jonathan I. Silvergerg AU - Howard Amital AU - Jason Zimmerman AU - Harry Heidecke AU - Avi Z Rosenberg AU - Gabriela Riemekasten AU - Yehuda Shoenfeld TI - The relationship between autoantibodies targeting GPCRs and the renin-angiotensin system associates with COVID-19 severity AID - 10.1101/2021.08.24.21262385 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.24.21262385 4099 - http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262385.short 4100 - http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262385.full AB - The coronavirus disease 2019 (COVID-19) can evolve to clinical manifestations resembling systemic autoimmune diseases, with the presence of autoantibodies that are still poorly characterized. To address this issue, we performed a cross-sectional study of 246 individuals to determine whether autoantibodies targeting G protein-coupled receptors (GPCRs) and renin-angiotensin system (RAS)-related molecules were associated with COVID-19-related clinical outcomes. Moderate and severe patients exhibited the highest autoantibody levels, relative to both healthy controls and patients with mild COVID-19 symptoms. Random Forest, a machine learning model, ranked anti-GPCR autoantibodies targeting downstream molecules in the RAS signaling pathway such as the angiotensin II type 1 and Mas receptor, and the chemokine receptor CXCR3 as the three strongest predictors of severe disease. Moreover, while the autoantibody network signatures were relatively conserved in patients with mild COVID-19 compared to healthy controls, they were disrupted in moderate and most perturbed in severe patients. Our data indicate that the relationship between autoantibodies targeting GPCRs and RAS-related molecules associates with the clinical severity of COVID-19, suggesting novel molecular pathways for therapeutic interventions.Competing Interest StatementThe authors declare that H.H. and K.S.F. are CellTrend managing directors and that GR is an advisor of the company CellTrend and earned an honorarium for her advice between 2011 and 2015. The other authors declare no competing interests.Funding StatementResearch Foundation (FAPESP grants 2018/18886-9, 2020/01688-0, and 2020/07069-0 to OCM; 2020/09146-1 to PPF) for financial support. Computational analysis was supported by FAPESP. This work was supported by the Deutsche Forschungsgemeinschaft (DFG) founding the excellence cluster Precision Medicine in Inflammation, project TI4 and CD1, by the COVID fond of Schleswig-Holstein as well as the DFG project RI 1056 11-1/2.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All healthy controls and patients provided written consent to participate in the study, which was performed in accordance with the Declaration of Helsinki and approved by the IntegReview institutional review board. In addition, this study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA reporting summary for this article is available as a Supplementary Information file. The source data underlying the Main and Supplementary Figures are provided as a Source Data file. All R packages used in this manuscript are described in the Reporting Summary.